Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of “Moderate Buy” from Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.3333.

EPRX has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Stifel Nicolaus initiated coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They set a “buy” rating and a $25.00 price target for the company. William Blair initiated coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th.

Eupraxia Pharmaceuticals Trading Up 3.0%

Shares of EPRX stock opened at $6.48 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. Eupraxia Pharmaceuticals has a 1 year low of $4.19 and a 1 year high of $9.32. The stock has a fifty day moving average of $6.91 and a two-hundred day moving average of $7.38. The firm has a market capitalization of $421.33 million, a PE ratio of -6.17 and a beta of 0.97.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, research analysts expect that Eupraxia Pharmaceuticals will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in EPRX. Seven Fleet Capital Management LP acquired a new stake in shares of Eupraxia Pharmaceuticals in the first quarter valued at $5,137,000. DV Trading LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the first quarter valued at $1,998,000. Bank of America Corp DE lifted its holdings in shares of Eupraxia Pharmaceuticals by 5.9% in the first quarter. Bank of America Corp DE now owns 268,221 shares of the company’s stock valued at $1,942,000 after buying an additional 14,900 shares during the period. Ally Bridge Group NY LLC lifted its holdings in shares of Eupraxia Pharmaceuticals by 66.0% in the first quarter. Ally Bridge Group NY LLC now owns 660,375 shares of the company’s stock valued at $4,781,000 after buying an additional 262,480 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of Eupraxia Pharmaceuticals by 33.2% in the first quarter. Royal Bank of Canada now owns 261,376 shares of the company’s stock valued at $1,893,000 after buying an additional 65,099 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.